Elutia Inc.
ELUT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001708527
No open-market purchases or sales by Elutia Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Elutia Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 32 | 31 | −1 |
| Shares | 13.2M | 17.2M | +4.03M (+30.6%) |
| Value | $49.3M | $43.6M | −$5.76M (−11.7%) |
New holders (5)
Institutions that held Elutia Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Arcus Capital Partners, LLC | 20,000 | $50.6K | 0.02% |
| Jane Street Group, LLC | 19,098 | $48.3K | 0.00% |
| Omers Administration Corp | 10,892 | $27.6K | 0.00% |
| Prudential Financial Inc | 10,400 | $26.3K | 0.00% |
| American Capital Advisory, LLC | 100 | $253 | 0.00% |
Sold out (6)
Institutions that held Elutia Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| 683 Capital Management, LLC | 80,758 | $302.0K |
| Citadel Advisors LLC | 22,431 | $83.9K |
| Citigroup Inc | 9,662 | $36.1K |
| UBS Group AG | 3,831 | $14.3K |
| JPMorgan Chase & Co | 41 | $153 |
| Lazard Asset Management LLC | 202 | $0 |